Comparison of the EORTC QLQ-EN24, FACT-En, and FEnSI-23 for assessing quality of life in endometrial cancer: a systematic review

Purpose of review Endometrial cancer is a prevalent gynecological malignancy with a rising incidence and substantial symptom burden. As treatments evolve, understanding patient-reported quality of life (QoL) has become critical. This review examines the characteristics, psychometric properties, and domain coverage of three key endometrial-cancer-specific patient-reported outcome measures to guide clinical and research applications. Recent findings The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer 24 (EORTC QLQ-EN24), the Functional Assessment of Cancer Therapy-Endometrial (FACT-En), and Functional Assessment of Cancer Therapy Endometrial Symptom Index (FEnSI-23) present varying structures, scopes, and focuses. The EORTC QLQ-EN24 provides detailed symptom assessment, particularly for treatment-induced effects, and has been validated in multinational settings. FACT-En offers a broader evaluation of physical, emotional, social, and functional well-being, supporting longitudinal and survivorship research. FEnSI-23, developed through patient-centered approaches, emphasizes disease-related symptoms and treatment side effects, taking the perspectives of underrepresented patient groups into account. Summary This review highlights significant differences in the scope, strengths, and psychometric properties of the EORTC QLQ-EN24, FACT-En, and FEnSI-23. While they demonstrate clinical research utility, gaps remain in cross-cultural validation and responsiveness. Prospective research should prioritize validation across diverse populations to further ascertain the measures’ reliability. Instrument selection should correlate with clinical requirements, with the EORTC QLQ-EN24 suited for detailed symptom assessment, the FACT-En for broader QoL evaluation, and the FEnSI-23 for patient-centered measurement of disease symptoms and treatment side effects.

Authors

Institutions

Publication Details

Journal
Current Opinion in Supportive and Palliative Care
Published
2026-05-28
DOI
https://doi.org/10.1097/spc.0000000000000805
Primary Topic
Endometrial and Cervical Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparison of the EORTC QLQ-EN24, FACT-En, and FEnSI-23 for assessing quality of life in endometrial cancer: a systematic review

Iwa Kong, Adrian Wai Chan, Eva Oldenburger, D Cella et al.
Current Opinion in Supportive and Palliative Care
Endometrial and Cervical Cancer Treatments
article

Comparison of the EORTC QLQ-EN24, FACT-En, and FEnSI-23 for assessing quality of life in endometrial cancer: a systematic review

Iwa Kong, Adrian Wai Chan, Eva Oldenburger, D Cella, Shely Kagan, Shirley SW Tse, Henry CY Wong, Edward Chow, Tiffany Zhang, Andrew Bottomley
article en

Abstract

Purpose of review Endometrial cancer is a prevalent gynecological malignancy with a rising incidence and substantial symptom burden. As treatments evolve, understanding patient-reported quality of life (QoL) has become critical. This review examines the characteristics, psychometric properties, and domain coverage of three key endometrial-cancer-specific patient-reported outcome measures to guide clinical and research applications. Recent findings The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer 24 (EORTC QLQ-EN24), the Functional Assessment of Cancer Therapy-Endometrial (FACT-En), and Functional Assessment of Cancer Therapy Endometrial Symptom Index (FEnSI-23) present varying structures, scopes, and focuses. The EORTC QLQ-EN24 provides detailed symptom assessment, particularly for treatment-induced effects, and has been validated in multinational settings. FACT-En offers a broader evaluation of physical, emotional, social, and functional well-being, supporting longitudinal and survivorship research. FEnSI-23, developed through patient-centered approaches, emphasizes disease-related symptoms and treatment side effects, taking the perspectives of underrepresented patient groups into account. Summary This review highlights significant differences in the scope, strengths, and psychometric properties of the EORTC QLQ-EN24, FACT-En, and FEnSI-23. While they demonstrate clinical research utility, gaps remain in cross-cultural validation and responsiveness. Prospective research should prioritize validation across diverse populations to further ascertain the measures’ reliability. Instrument selection should correlate with clinical requirements, with the EORTC QLQ-EN24 suited for detailed symptom assessment, the FACT-En for broader QoL evaluation, and the FEnSI-23 for patient-centered measurement of disease symptoms and treatment side effects.

Current Opinion in Supportive and Palliative Care
Northwestern University (US), BC Cancer Agency (CA), Hospital Authority (HK), Sunnybrook Health Science Centre (CA), University of Toronto (CA), Leiden University Medical Center (NL), United Christian Hospital (CN), Spinal Cord Injury BC (CA), Health Sciences Centre (CA), Princess Margaret Hospital (NZ), Princess Margaret Hospital (HK), Queen Elizabeth Hospital (CN), KU Leuven (BE)
Openalex Percentile: Top 5%
Endometrial and Cervical Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.